Dovitinib
- Generic Name
- Dovitinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21FN6O
- CAS Number
- 405169-16-6
- Unique Ingredient Identifier
- I35H55G906
- Background
Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with different cancers, including acute myeloid leukemia (AML) and multiple myeloma. Chiron currently has three ongoing Phase I clinical trials for dovitinib.
- Indication
Investigated for use/treatment in multiple myeloma and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
- First Posted Date
- 2011-12-02
- Last Posted Date
- 2018-02-09
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 12
- Registration Number
- NCT01484041
- Locations
- ๐บ๐ธ
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function
- First Posted Date
- 2011-09-29
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT01443481
- Locations
- ๐บ๐ธ
University of California at Los Angeles Dept. of UCLA (4), Los Angeles, California, United States
๐บ๐ธDuke University Medical Center DUMC, Durham, North Carolina, United States
๐บ๐ธCancer Therapy & Research Center / UT Health Science Center SC, San Antonio, Texas, United States
Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258
- First Posted Date
- 2011-09-27
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT01440959
- Locations
- ๐ฐ๐ท
Asan Medical Center, University of Ulsan College of Medicine, Seoul,, Korea, Republic of
TKI 258 in Von Hippel-Lindau Syndrome (VHL)
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT01266070
- Locations
- ๐บ๐ธ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
TKI258 for Metastatic Inflammatory Breast Cancer Patients
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT01262027
- Locations
- ๐บ๐ธ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 162
- Registration Number
- NCT01232296
- Locations
- ๐น๐ญ
Novartis Investigative Site, Songkla, Thailand
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 564
- Registration Number
- NCT01223027
- Locations
- ๐บ๐ธ
Deke Slayton Cancer Center Deke Slayton Cancer Center (2), Webster, Texas, United States
๐บ๐ธUniversity of Kansas Cancer Center Univ of KS, Kansas City, Kansas, United States
๐บ๐ธRockwood Clinic Spokane Location, Spokane, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.